CAS: 92276-38-5; 6-Bromo-3H-[1,2,3]Triazolo[4,5-B]Pyridine

相似化合物

273-34-7 1257554-00-9 408314-14-7

上下游产品

5-bromo-pyridine-2,3-diamine 5-bromo-3-nitro-pyridin-2-ylamine 6-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-[1,2,3]triazolo[4,5-b]pyridine

📜2-氨基-5-溴-3-硝基吡啶置于盐酸,硫酸,Tin(Ll) Chloride体系中,用 水 作为反应溶剂,化学反应生成 6-溴-1H-1,2,3-三唑[4,5-B]吡啶
参考文献:新型卤代偶氮[4,5-B]吡啶作为ck2激酶抑制剂的合成,生物学特性和结构研究
标题:新型卤代偶氮[4,5-B]吡啶作为ck2激酶抑制剂的合成,生物学特性和结构研究
摘要:新的卤代 1 H-三唑并[4,5-B]吡啶和 1 H-咪唑并[4,5-B]吡啶作为已知 Ck2 抑制剂的类似物合成:4,5,6,7-四溴-1 H-苯并三唑 (Tbbt) 和 4,5,6,7-四溴-1 H-苯并咪唑 (Tbbi).确定了它们对重组人 Ck2α,Ck2α' 和 Pim1 激酶活性的影响.最有效的抑制剂是二卤代和三卤代 1 H-三唑并[4,5-B]吡啶(4A,5A和10A),Ic为 50Ck2α 的值分别为 2.56,3.82 和 3.26 μm.此外,评估了所有最终化合物对癌细胞系 Mcf-7(人乳腺癌)和 Ccrf-Cem(t 淋巴母细胞白血病)活力的影响.最后,获得了ck2α 1-335与抑制剂4A,5A和10A复合物的三种晶体结构.此外,新方案用于获得与四种抑制剂(4A,5A,5B,10A)复合的 Ck2α' Cys336Ser的高分辨率晶体结构.
DOI:10.1016/j.Bioorg.2020.104502

专利信息

专利号:WO-2024233563-A1
优先权日:2023-05-09
标 题:6,6-fused bicyclic amides and compositions for use as 15-prostaglandin dehydrogenase modulators
发明人：GREENMAN KEVIN LLOYD; WANG HUI-LING; WEIRES NICHOLAS ANTHONY; ALLEN JOHN G; AMEGADZIE ALBERT K; BOURBEAU MATTHEW P; LI KEXUE
权利人:AMGEN INC
摘要:The present disclosure provides novel 15-hydroxy-prostaglandin dehydrogenase inhibitors, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions in treating 15-hydroxy-prostaglandin dehydrogenase-mediated disease. Also provided are methods of making such compounds and intermediates thereof. The compounds have a structure of Formula (I): or a pharmaceutically acceptable salt thereof; wherein is Formula (i) or Formula (ii) Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).

专利号:US-2024409557-A1
优先权日:2023-05-09
标 题 :5,6-fused and 6,6-fused bicyclic alcohols and ethers and compositions for use as 15-prostaglandin dehydrogenase modulators
发明人：GREENMAN KEVIN LLOYD; PICKRELL ALEXANDER J; LI KEXUE; AMEGADZIE ALBERT K; WANG HUI-LING; WEIRES NICHOLAS ANTHONY; ALLEN JOHN G; BOURBEAU MATTHEW P
权利人:AMGEN INC
摘要:The present disclosure provides novel 15-hydroxy-prostaglandin dehydrogenase inhibitors, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions in treating 15-hydroxy-prostaglandin dehydrogenase-mediated disease. Also provided are methods of making such compounds and intermediates thereof. The compounds have a general Formula (A).Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (A).

专利号:US-9751874-B2
优先权日:2014-12-17
标题:Hydroxy containing FXR (NR1H4) modulating compounds
发明人：GEGE CHRISTIAN; KINZEL OLAF; KREMOSER CLAUS; SCHMITT AARON C
权利人:GILEAD SCIENCES INC
摘要:The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.